The company will report its earnings for FY 2017 on 03/14/2018. Generally, the company reports earnings in line with the consensus. In recent months, the 3 analysts from Thomson Reuters consensus have not revised their EPS estimates.
Annual earnings per share is expected at 12.68 CHF for 2017 (+ 80.1% from 2016). A summary of annual publications and estimates is available below.
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
SIEGFRIED HOLDING AG 
